-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Rockefeller Capital Management L.P. Grows Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Rockefeller Capital Management L.P. Grows Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Rockefeller Capital Management L.P. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 20.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 719 shares of the medical research company's stock after acquiring an additional 124 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in Bio-Rad Laboratories were worth $299,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the company. Sentry Investment Management LLC grew its holdings in Bio-Rad Laboratories by 16.5% in the second quarter. Sentry Investment Management LLC now owns 148 shares of the medical research company's stock valued at $73,000 after purchasing an additional 21 shares during the last quarter. Arizona State Retirement System grew its holdings in Bio-Rad Laboratories by 0.4% in the second quarter. Arizona State Retirement System now owns 6,245 shares of the medical research company's stock valued at $3,091,000 after purchasing an additional 23 shares during the last quarter. Mather Group LLC. grew its holdings in Bio-Rad Laboratories by 6.8% in the first quarter. Mather Group LLC. now owns 377 shares of the medical research company's stock valued at $212,000 after purchasing an additional 24 shares during the last quarter. Kestra Private Wealth Services LLC grew its holdings in Bio-Rad Laboratories by 3.2% in the second quarter. Kestra Private Wealth Services LLC now owns 809 shares of the medical research company's stock valued at $400,000 after purchasing an additional 25 shares during the last quarter. Finally, Raymond James Trust N.A. grew its holdings in Bio-Rad Laboratories by 5.5% in the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company's stock valued at $283,000 after purchasing an additional 26 shares during the last quarter. Institutional investors and hedge funds own 64.35% of the company's stock.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Stock Up 0.7 %
Shares of NYSE:BIO opened at $467.46 on Wednesday. The stock's 50-day moving average price is $428.58 and its two-hundred day moving average price is $446.98. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $670.61. The firm has a market cap of $13.94 billion, a price-to-earnings ratio of -2.32 and a beta of 0.91.
Analyst Upgrades and Downgrades
Several analysts have weighed in on BIO shares. TheStreet lowered Bio-Rad Laboratories from a "c" rating to a "d+" rating in a report on Thursday, October 27th. Royal Bank of Canada began coverage on Bio-Rad Laboratories in a research note on Tuesday, December 6th. They set an "outperform" rating and a $565.00 price objective on the stock. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. Finally, Credit Suisse Group decreased their price objective on Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating on the stock in a research note on Friday, October 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
洛克菲勒资本管理公司(Rockefeller Capital Management L.P.)最近提交给美国证券交易委员会的Form 13F文件显示,该公司在第三季度增持了Bio-Rad实验室公司的股份20.8%。该机构投资者在本季度增持了124股后,持有这家医疗研究公司的719股股票。截至洛克菲勒资本管理公司最近向美国美国证券交易委员会提交的文件,该公司所持Bio-Rad实验室股份价值29.9万美元。
其他几家大型投资者最近也买卖了该公司的股票。第二季度,哨兵投资管理公司对Bio-Rad实验室的持股增加了16.5%。在上个季度增持了21股股票后,哨兵投资管理公司现在拥有148股这家医疗研究公司的股票,价值7.3万美元。亚利桑那州退休系统在第二季度增加了对Bio-Rad实验室的持有量0.4%。亚利桑那州退休系统现在拥有这家医疗研究公司的6,245股股票,价值3,091,000美元,此前在上个季度又购买了23股。Mather Group LLC.第一季度,其在Bio-Rad实验室的持股增加了6.8%。Mather Group LLC.在上个季度又购买了24股后,现在拥有377股这家医疗研究公司的股票,价值21.2万美元。Kestra Private Wealth Services LLC在第二季度增持了Bio-Rad实验室3.2%的股份。Kestra Private Wealth Services LLC在上个季度又购买了25股,现在拥有809股这家医疗研究公司的股票,价值40万美元。最后,Raymond James Trust N.A.在第一季度增持了Bio-Rad实验室5.5%的股份。雷蒙德·詹姆斯信托公司(Raymond James Trust N.A.)在上个季度又购买了26股,现在拥有501股这家医疗研究公司的股票,价值28.3万美元。机构投资者和对冲基金持有该公司64.35%的股票。
到达Bio-Rad实验室警报:Bio-Rad实验室股票上涨0.7%
纽约证券交易所:BIO的股票周三开盘报467.46美元。该股的50日移动均线价格为428.58美元,200日移动均线价格为446.98美元。该公司的流动比率为5.50,速动比率为4.30,债务权益比率为0.14。Bio-Rad实验室,Inc.的12个月低点为344.63美元,12个月高位为670.61美元。该公司的市值为139.4亿美元,市盈率为-2.32倍,贝塔系数为0.91。
分析师升级和下调评级
几位分析师对Bio的股价进行了分析。华尔街在10月27日星期四的一份报告中将Bio-Rad实验室的评级从“c”下调至“d+”。加拿大皇家银行在12月6日星期二的一份研究报告中开始对Bio-Rad实验室进行报道。他们为该股设定了“跑赢大盘”的评级和565.00美元的目标价。在1月18日星期三的一份研究报告中,StockNews.com将Bio-Rad实验室的评级从“买入”下调至“持有”。最后,瑞士信贷集团将Bio-Rad实验室的目标价从715.00美元下调至640.00美元,并在10月28日星期五的一份研究报告中对该股设定了“跑赢大盘”的评级。一名投资分析师对该股的评级为持有,四名分析师对该公司的评级为买入。根据MarketBeat的数据,该股的共识评级为“适度买入”,共识目标价为651.25美元。Bio-Rad实验室公司简介
(获取评级)
Bio-Rad实验室公司致力于开发和生产用于生化、制药和其他生命科学研究应用的特殊化学品。它通过生命科学和临床诊断部门开展业务。生命科学部门开发、制造和销售试剂、仪器和实验室仪器。
推荐故事
- 免费获取StockNews.com关于Bio-Rad实验室的研究报告(BIO)
- Verizon,Charge在过去的一个月里趋势更高:他们现在购买吗?
- 股利之王Sysco:逢低买入
- 天才集团股票1600%的涨幅合理吗?
- 在进一步审查后,投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖出另一个收购机会吗?
想看看其他对冲基金持有哪些传记吗?访问HoldingsChannel.com,获取Bio-Rad实验室,Inc.(纽约证券交易所:Bio-Get Rating)的最新13F文件和内幕交易。
每天收到Bio-Rad实验室的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bio-Rad实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧